EUCTR2016-000154-34-DE进行中（未招募）1 期
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®,as an Active Control, on Lung Function over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD - TELOS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Give their signed written informed consent to participate
- •2. Are at least 40 years of age and no older than 80 years
- •3. Moderate to very severe COPD patients who are symptomatic
- •4. Must be receiving one or more inhaled bronchodilators as maintenance therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1310
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1110
排除标准
- •1. Current diagnosis of asthma,
- •2. COPD due to a1-Antitrypsin Deficiency
- •3. Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months
- •4. Long-term-oxygen therapy (= 15 hours a day).
研究者
相似试验
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects with Moderate to Very Severe COPD (sophos)EUCTR2016-000155-28-GBPearl Therapeutics, Inc. (Pearl)1,860
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel Group, Multi-Center 24 Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent AsthmaSubjects With Persistent AsthmaEUCTR2020-000532-22-Outside-EU/EEAPearl Therapeutics Inc.1,071
招募中
1 期
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)CTIS2023-507407-59-00Astrazeneca AB5,000
进行中（未招募）
1 期
Study of Lung Function and Health Outcome Improvement in Obstructive Lung DiseaseEUCTR2016-000154-34-CZPearl Therapeutics, Inc.2,420
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of PT009 compared to PT005 onCOPD Exacerbations over a 52-Week Period in Subjects with Moderate toVery Severe COPD (sophos)Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2016-000155-28-ESPearl Therapeutics, Inc. (Pearl)2,241